drugset / Trial / NCT03485144

A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan

NCT03485144 ↗

Phase 2 Completed 54 enrolled Medigen Vaccine Biologics Corp.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The goal of this study is to determine the immunogenicity and safety of TV003(TetraVax-DV), a live attenuated tetravalent dengue vaccine candidate, in healthy human subjects in Taiwan

Timeline

Start
2017-12-12
Primary completion
2019-05-10
Completion
2019-05-10

Drugs

EvaluationDrugModalityDoseRoute
Subject TV003 Vaccine — —

Indications